Company profile: 4basebio
1.1 - Company Overview
Company description
- Provider of DNA manufacturing technologies and products for the gene therapy market, including double-stranded DNA formats: hpDNA (hairpinned ends for viral and non-viral vectors), osDNA (with nucleotide modifications for degradation resistance and tunable immunostimulation for DNA vaccines), opDNA and oeDNA for mRNA production and genome editing, the Hermes non-viral delivery platform, and DNA template manufacturing for AAV/Lentivirus with small-scale AAV production and purification.
Products and services
- HpDNA: Hairpin-ended, double-stranded linear DNA with single-strand hairpins at both ends, suitable for viral and non-viral vector applications serving the gene therapy market
- DNA template production services: Small-scale manufacturing of DNA templates for AAV and Lentivirus production, including small scale AAV production and purification for gene therapy manufacturing
- OeDNA: Open-ended, linear double-stranded DNA product for mRNA production and genome editing applications, suited to workflows in the fast-growing gene therapy market
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to 4basebio
MyOme
HQ: United States
Website
- Description: Provider of a comprehensive genetic testing platform, MyOme Personal Genome, using whole genome sequencing to deliver insights into disease risk, medication response, and other health information. Offers Personal Genome reports identifying potential gene mutations and medication responses, and is developing Integrated Personal Risk Score Reports that combine genetic analysis with clinical risk factors for conditions like coronary artery disease and breast cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MyOme company profile →
QurAlis
HQ: United States
Website
- Description: Provider of precision medicines for ALS and FTD, including therapeutic candidates QRL-201 to restore STMN2 expression and QRL-101 to reduce hyperexcitability-induced neurodegeneration by opening Kv7 channels, and platforms: QR43 to discover precision therapies for TDP-43-related diseases and FlexASO to develop antisense oligonucleotides that modulate RNA splicing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full QurAlis company profile →
Avrobio
HQ: United States
Website
- Description: Provider of clinical-stage cell and gene therapies under development targeting cancer and rare disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avrobio company profile →
GeneInsight
HQ: United States
Website
- Description: Provider of an IT platform that streamlines data interpretation and management; GeneInsight Suite has been in clinical use and evolving since 2005, developed at Partners HealthCare in collaboration with leading geneticists, laboratory operations personnel, practicing physicians, and IT professionals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeneInsight company profile →
AviaraDx
HQ: United States
Website
- Description: Provider of molecular diagnostic tests in oncology, discovering, developing, and commercializing new tests that enable physicians to personalize cancer treatment through better understanding of the molecular biology underlying a patient's tumor and improve the classification of cancer, supporting physicians.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AviaraDx company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for 4basebio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to 4basebio
2.2 - Growth funds investing in similar companies to 4basebio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for 4basebio
4.2 - Public trading comparable groups for 4basebio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →